Kytril Inj/Inf

Granisetron, the active ingredient in Kytril Inj/Inf, is a 5-HT3 receptor antagonist presented as an injection solution for intravenous use. It treats chemotherapy‑induced nausea and vomiting and postoperative nausea and vomiting in patients receiving cytotoxic therapy or undergoing surgery.

GNH USA supplies Kytril Inj/Inf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Kytril Inj/Inf is a selective 5‑HT3 receptor antagonist used to control nausea and vomiting associated with chemotherapy and surgery.

- Chemotherapy‑induced nausea and vomiting: prevents and controls nausea and vomiting caused by cytotoxic chemotherapy. - Postoperative nausea and vomiting: reduces the incidence and severity of nausea and vomiting after surgical procedures. - Radiation‑induced nausea and vomiting: helps manage nausea and vomiting that may occur during radiation therapy.

Kytril Inj/Inf may be associated with a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Headache: mild to moderate headache reported. - Constipation: reduced bowel movements or hard stools. - Dizziness: sensation of light‑headedness or vertigo. - Fatigue: feeling unusually tired or weak. - Diarrhoea: loose stools occurring intermittently. - Injection site reactions: pain, erythema or swelling at the site of administration.

Serious or Rare Side Effects: - QT interval prolongation: potential cardiac arrhythmia risk. - Severe allergic reaction (anaphylaxis): rare but may be life‑threatening. - Arrhythmia: irregular heart rhythm in susceptible individuals. - Severe hypotension: marked drop in blood pressure. - Serotonin syndrome: rare condition with neuromuscular and autonomic disturbances. - Cardiac arrest: extremely rare but reported in isolated cases.

When using Kytril Inj/Inf, clinicians should consider several safety measures.

- Cardiac assessment: evaluate baseline ECG and monitor for QT prolongation. - Concomitant QT‑prolonging drugs: avoid or use with caution to reduce arrhythmia risk. - Hepatic impairment: adjust dosing or monitor closely in patients with liver dysfunction. - Allergic reactions: discontinue immediately if signs of severe hypersensitivity appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kytril Inj/Inf can interact with other medicines, influencing its safety and efficacy.

Major Interactions (Avoid): - Other QT‑prolonging agents: increased risk of cardiac arrhythmias. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise granisetron plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce granisetron effectiveness. - Anticholinergic drugs: may exacerbate constipation. - Additional serotonergic antiemetics (e.g., ondansetron): potential additive serotonergic effects.